TriSalus Life Sciences
TLSI
28 hedge funds and large institutions have $9.21M invested in TriSalus Life Sciences in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
8% more funds holding
Funds holding: 26 → 28 (+2)
3.07% more ownership
Funds ownership: 3.51% → 6.57% (+3.1%)
2% more capital invested
Capital invested by funds: $9.03M → $9.21M (+$173K)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.11M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$1.82M |
| 3 |
EAM
Exos Asset Management
New York
|
+$1.42M |
| 4 |
DFO
Duquesne Family Office
New York
|
+$941K |
| 5 |
Millennium Management
New York
|
+$892K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LNWWM
Laird Norton Wetherby Wealth Management
San Francisco,
California
|
-$341K |
| 2 |
Goldman Sachs
New York
|
-$267K |
| 3 |
BlackRock
New York
|
-$101K |
| 4 |
CWM
Connecticut Wealth Management
Farmington,
Connecticut
|
-$99.5K |
| 5 |
TWP
Tyche Wealth Partners
Plano,
Texas
|
-$97.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $110 | -$89.4K | -10,539 | -100% |
|
|
CS
27
Clear Street
New York
| $6 | – | – | – |
|
|
DM
28
Deerfield Management
New York
| $6 | – | – | – |
|
|
LNWWM
29
Laird Norton Wetherby Wealth Management
San Francisco,
California
| – | -$341K | -34,950 | Closed |
|
|
TWP
30
Tyche Wealth Partners
Plano,
Texas
| – | -$97.5K | -10,000 | Closed |
|
31
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$53.5K | -5,490 | Closed |
|
32
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$3 | -291 | Closed |
|
TLSI Hedge Fund Activity: Q2 2024 in Review
28 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q2 2024, worth a combined $9.21M — up 1.9% from $9.03M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TLSI positions and 4 closed out — a net gain of 2 holders — while 6 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.11M. The largest seller was Laird Norton Wetherby Wealth Management, exiting entirely with an estimated $341K sold.
- 28 institutional investors held TriSalus Life Sciences (TLSI) as of Q2 2024, up from 26 in Q1 2024.
- Funds reported $9.21M of TriSalus Life Sciences stock for Q2 2024, up 1.9% quarter-over-quarter.
- 6 funds opened new TriSalus Life Sciences positions in Q2 2024 and 4 closed out, a net change of +2 holders.
- The largest TriSalus Life Sciences buyer in Q2 2024 was Vanguard Group, an estimated $2.11M added.
- The largest TriSalus Life Sciences seller in Q2 2024 was Laird Norton Wetherby Wealth Management, an estimated $341K sold.
Based on aggregated 13F filings for Q2 2024.